* Celsion Corp., of Columbia, Md., completed a $1 million private placement and said it plans to redeem, if and when permitted, certain outstanding warrants that could raise another $1 million to $3 million. The company is developing treatment systems for cancer and benign prostatic hyperplasia, using focused heat delivered by microwave technology.
* Chiron Corp., of Emeryville, Calif., received approval to market its diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP), Triacelluvax, in the 15 European Union countries. It will start marketing efforts soon in all except Germany. Also, Chiron withdrew its DTaP marketing application in the U.S., citing competition and a refocus of the company's product portfolio.
* Cephalon Inc., of West Chester, Pa., launched Provigil (modafinil) tablets in the Republic of Ireland for the treatment of narcolepsy. The FDA approved Provigil in December, and Cephalon said the company expects to launch the product in the U.S. later this month.
* GeneLabs Technologies Inc., of Redwood City, Calif., said it has been notified by the Defense Advanced Research Projects Agency that the company's three-year grant will be funded for a second year, with funding of $4.8 million. The first year was funded at $3.8 million. GeneLabs is conducting research into biological defense.
* Genome Therapeutics Corp., of Waltham, Mass., said it attained a research milestone in its collaboration with Schering-Plough Corp., of Madison, N.J., to discover asthma therapeutics. The milestone triggered an undisclosed payment to Genome Therapeutics.
* Genzyme Corp., of Cambridge, Mass., said its Genzyme Tissue Repair division found 85 percent of 40 patients treated with its Carticel cartilage-repair product showed improvement three years after surgery in four measurement areas. The results are in the fifth report of the company's Cartilage Report Registry, and are the first to show three-year data.
* Hyseq Inc., of Sunnyvale, Calif., said it acquired certain exclusive rights to ectoapyrase anti-clotting products from Imperial Cancer Research Technology Ltd., of London, a wholly owned subsidiary of England's Imperial Cancer Research Fund. The products could help prevent or treat blood-vessel blockage.
* LJL BioSystems Inc., of Sunnyvale, Calif., and Sumitomo Corp., of Tokyo and Osaka, Japan, signed an exclusive distribution agreement, giving Sumitomo rights to sell LJL's drug-discovery products in Japan. Terms were not disclosed.
* Neotherapeutics Inc., of Irvine, Calif., completed the placement of $4 million in stock with conversion features to two institutional investors, with an option to sell $2 million more in preferred stock to the investors commencing in 180 days.
* NeXstar Pharmaceuticals Inc., of Boulder, Colo., began the first in a series of planned Phase I trials of NX 211, a liposomal form of the cancer drug lurtotecan, a proprietary topoisomerase inhibitor. The first trials are being conducted in the Netherlands. Additional Phase I studies are planned for the U.S. and Canada.
* Ontogen Corp., of Carlsbad, Calif., completed a Phase I study of OCI44-093, a P-glycoprotein inhibitor being developed to reverse the effects of multidrug resistance in patients undergoing chemotherapy treatment. The company plans to find a partner to help further develop the compound.
* Ontogeny Inc., of Cambridge, Mass., signed a deal with Becton Dickinson Co., of Franklin Lakes, N.J., to focus on cell-based therapy for Type I diabetes and the segment of Type II diabetes characterized by insulin secretion defects. Financial terms were not disclosed.
* OraPharma Inc., of Warminster, Pa., gained an exclusive license from Children's Medical Center Corp., of Boston, to three products focused on bone and soft tissue regeneration for the dentistry and orthopedics markets. The three products - OsteoIntegrin, OsteoMorphin and Rapid Implant Stabilizer - have applications in humans and animals.
* Osteotech Inc., of Eatontown, N.J., completed its acquisition of 90 percent of OST Development SA, of Clermont-Ferrand, France, for about $1.5 million. Osteotech, which may buy the rest of the company at a price to be determined, intends to use France as the initial marketing focus and hub of operations in Europe.
* Pangea Systems Inc., of Oakland, Calif., said its computational tools are being used by Hoechst Marion Roussel Inc., of Frankfurt, Germany, and the Hoechst-ARIAD Genomics Center (a joint venture of Hoechst Marion Roussel and ARIAD Pharmaceuticals Inc., of Cambridge, Mass.) to design custom gene-expression chips from full-length chips and clustered gene fragments.
* Periodontix Inc., of Watertown, Mass., was awarded a two-year $200,000 grant from the Cystic Fibrosis Foundation to develop its histanin peptide, P-113, to treat chronic lung infections associated with the disease. The company plans to license rights to that indication.
* Shaman Pharmaceuticals Inc., of South San Francisco, said NASDAQ notified the company its stock will be moved from the National Market listing to the NASDAQ Bulletin Board, effective immediately.